US Penny Stocks To Consider In December 2024

In This Article:

As the Nasdaq Composite reaches new heights and Bitcoin surges to unprecedented levels, the U.S. market is experiencing a mix of optimism and caution, with investors keenly watching upcoming Federal Reserve decisions. In this context, penny stocks—often representing smaller or emerging companies—remain a compelling area for those seeking growth opportunities. By focusing on firms with solid financial foundations and clear growth potential, investors might uncover significant value in these often-overlooked segments of the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.42

$2.03B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$128.29M

★★★★★★

BAB (OTCPK:BABB)

$0.874625

$6.32M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.87

$89.78M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.23

$8.25M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.50

$48.84M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$0.875

$13.39M

★★★★★☆

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8366

$75.59M

★★★★★☆

Click here to see the full list of 717 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Organogenesis Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $450.76 million.

Operations: The company's revenue is primarily generated from its regenerative medicine segment, amounting to $455.04 million.

Market Cap: $450.76M

Organogenesis Holdings Inc., with a market cap of US$450.76 million, has shown financial resilience despite being unprofitable. It reported significant revenue from its regenerative medicine segment, reaching US$455.04 million. The company is executing strategic initiatives such as a share repurchase program and expansion of manufacturing capacity in Rhode Island, contingent on tax incentives. Financially, Organogenesis's debt level is well-managed with cash exceeding total debt and operating cash flow covering debt obligations effectively. Although the stock remains volatile, it trades at a good value compared to peers and analysts anticipate potential price appreciation.